Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 273,433 shares of the pharmaceutical company’s stock after selling 3,763 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Vertex Pharmaceuticals were worth $123,964,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Danske Bank A S acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $64,417,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Vertex Pharmaceuticals by 3.8% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 544,978 shares of the pharmaceutical company’s stock worth $213,435,000 after purchasing an additional 20,053 shares during the last quarter. Legacy Capital Group California Inc. acquired a new position in Vertex Pharmaceuticals in the third quarter worth about $956,000. ING Groep NV bought a new stake in Vertex Pharmaceuticals in the third quarter valued at about $4,695,000. Finally, Victory Capital Management Inc. increased its holdings in Vertex Pharmaceuticals by 4.3% in the third quarter. Victory Capital Management Inc. now owns 2,247,566 shares of the pharmaceutical company’s stock valued at $880,237,000 after buying an additional 92,402 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on VRTX. Oppenheimer increased their target price on Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an “outperform” rating in a report on Tuesday, March 10th. Weiss Ratings upgraded Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, May 18th. Wall Street Zen lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 30th. Barclays raised their price objective on Vertex Pharmaceuticals from $607.00 to $615.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, HC Wainwright lifted their price objective on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Twenty-two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $555.91.

Insiders Place Their Bets

In other news, EVP Joy Liu sold 1,104 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $425.02, for a total value of $469,222.08. Following the transaction, the executive vice president owned 20,729 shares of the company’s stock, valued at $8,810,239.58. The trade was a 5.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 318 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $423.73, for a total transaction of $134,746.14. Following the completion of the sale, the director owned 4,924 shares in the company, valued at $2,086,446.52. The trade was a 6.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 11,133 shares of company stock worth $4,973,106. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex received bullish attention from market commentary highlighting that Wall Street remains interested in the stock despite a bearish “death cross” technical setup, suggesting investors are focusing more on the company’s fundamentals than the chart pattern. Article Title
• Positive Sentiment: The company announced new CASGEVY data at the European Hematology Association Congress, including the first European presentation of results in children ages 5–11 and additional global regulatory submissions, which could support longer-term growth for the gene-editing therapy. Article Title
• Positive Sentiment: Analysts and media coverage have been broadly upbeat on Vertex, including pieces describing it as a favored healthcare stock and a stock some investors view as attractive to buy now, reinforcing confidence in the name. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Vertex to $19.24 from $19.36, a small revision that may not materially change the long-term outlook but is a minor headwind for sentiment. Article Title
• Negative Sentiment: The stock has also experienced a recent pullback in some sessions, reflecting normal volatility and some profit-taking even as the broader narrative remains constructive. Article Title

Vertex Pharmaceuticals Trading Down 0.0%

VRTX stock opened at $444.92 on Friday. The firm’s 50-day moving average is $437.14 and its two-hundred day moving average is $452.33. The company has a market capitalization of $112.92 billion, a price-to-earnings ratio of 26.39, a price-to-earnings-growth ratio of 1.90 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $507.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping analysts’ consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The company had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $2.99 billion. During the same quarter in the previous year, the business earned $4.06 EPS. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 17.02 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.